1445. Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers

BACKGROUND: High-dose extended-infusion cefepime-tazobactam (FEP-TAZ) is in clinical development at 2g/2g q8 hours administered over 90 minutes. We evaluated the potency and spectrum of activity of FEP-TAZ, ceftolozane–tazobactam (C-T), ceftazidime–avibactam (CAZ-AVI), and comparators tested against...

Descripción completa

Detalles Bibliográficos
Autores principales: Sader, Helio S, Carvalhaes, Cecilia G, Shortridge, Dee, Huband, Michael D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809413/
http://dx.doi.org/10.1093/ofid/ofz360.1309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809413/
http://dx.doi.org/10.1093/ofid/ofz360.1309

Ejemplares similares